Member Info for ROCKZ

For whatever reason it seems a decision has been made to go to ground on the comms.
I have also had no reply to a couple of emails and although It’s not ideal, I do feel there’s a bigger picture in the background which will become more visible in the near future.

Haha that’s class.

No worries Noose, TILS time will come, blue skies ahead. Just a game of patience at the moment.

Noose, no relevance here I’m afraid. They are referring to tumor infiltrating lymphocytes (tils).
Just a coincidence that TILS is operating in this same area, or was before the demerger.

Don’t worry Markat, I’ve got the snorkel on aswell at the moment, also in deep but not concerned.
I’ve seen this share price motor by 20 per cent plus in a day on many occasions now.
Currently way undervalued in my book. I’m looking for £2.60 before I even consider taking 10 per cent of my holding off the table.

It just needs one politician or someone presently operating in those circles eg. Chris Witty, Patrick Vallance to reference Foralumab and this could go off the scale.

Markat, Paul is a credible poster who has had replies from the company previously.
If the UK government show an interest in what TILS is offering the SP will go through the roof.
We are lucky that we have the inside knowledge of a fully human monoclonal antibody which is more cost effective to produce than any other Mab out there and easier to administer than any other Mab out there.
Cheers for the info Paul.

Agreed guys although seriously struggling to gain any traction at the moment.
Some positive spin from outside the company would be most welcome.
Radio silence still from within the company but I get the feeling something nice is cooking.

Bad drop for ProventionBio on Friday. Maybe why KS avoided the diabetes market.
Foralumab is particularly novel in its approach so should be clear of a similar problem in the future.

https://finance.yahoo.com/amphtml/news/provention-bio-shares-crash-40-113430352.html

Yeah not impressed either with HL recently. They have a load of people working from home, that’s why they can’t do Bed and ISA’s at the moment even though they are still advertising it. Ha.

I would like to see someone with substance from outside the company champion Foralumab and it’s potential to treat Covid. We know the massive benefits compared to the competition, cost, less toxicity etc.
It feels like the guys at the top of the company know how big Foralumab could be but are wary of counting their chickens before they hatch. This is biotech after all and trials still fail in the Phase3 stage so who can blame them.
I would be the same. For most of us, if you get too ****y in life things have a habit of coming back to bite you.
Gabrielle has shown that he can be pretty ruthless when the time is right by calling out OncotypeDX as being inferior to StemprintER.
No doubt he will do the same to Tocilizumab when the time is right for Foralumab and it achieves approval (fingers crossed).

Pretty poor from HL, they are not doing Bed & ISA’s at the moment so you end up being out the market for a couple of days if you want to transfer shares across from a share/fund account whilst the transaction clears.

Really good article Whimax and agreed, quite a few similarities.
Well summed up at the end-
If you’re investing for the short term (less than five years) then you must expect these shenanigans.
They aren’t going away.
Buy, hold, and don’t look at it.

We all want this to fly but it could be a while yet..

Totally right about the investor relations though Chris. I’m going to word an email to the company this afternoon, they need to employ someone to solely manage this department.
They are going to lose some good investors here if they continue with a slack approach to Investor relations.
As Roker would say, I’ve got the ranch invested here so would especially expect better IR, as would any investor who deserves the decency of a reply.

Crypto Chris, if you don’t mind I would like to revise number 2 for you to ‘not delivering commitments on time’.
The company have a track record for eventually delivering.
Agreed, Investor relations could be a lot better and definitely an area the company need to improve on.
Timelines could definitely be better but most companies are suffering the same in these unprecedented times. Good luck

Thinkin, the figures stated are certainly not meant as ‘a deramp’.
Quite the opposite, the company are fully cashed up for the next couple of years at this burn rate.
The words came from the CEO and the additional costs were necessary to grow the company, Phase2 trials, more staff etc etc.

https://uk.finance.yahoo.com/amphtml/news/tiziana-life-sciences-participate-fireside-113100658.html

No worries Whimax. My post from 22nd January after the Fireside video call:
Just managed to catch up with the KS video.
Company burn rate of cash is currently $500,000 a month.
From March/April this will go up to $1.5m-$1.7m a month.
A strong indication that a Phase 2b trial with larger numbers has been programmed in for the Foralumab treatment of Covid.
I haven’t sold a single share in this company and don’t plan to for a while yet.
The company continue to deliver on their promises including StemprintER demerger and main market listing. So what if delivery timelines are a little bit out, every timeline in business seems to be a little bit out within the last year and there’s a good reason why!
I strongly believe now that this company is going to be bigger than most of us think.
Another demerger within the next couple of years could also be on the cards.

The RNS today relating to the Foralumab treatment for a patient with SPMS seemed to come left of field.
I don’t remember the company mentioning SPMS previously and it’s my theory that perhaps the patient had approached the company after previously taking part in the Phase1 trial for progressive multiple sclerosis or through hearing of Dr Weiners excellent work at the Harvard Medical School.
Either way, the chance to monitor one patient so closely seems like an opportunity the company couldn’t turn down as they glean more and more information along the way.

KewJosh, to answer your question from this morning:
Company burn rate of cash was $500,000 a month.
From March/April 2021 this has increased to $1.5m-$1.7m a month.